logo
Plus   Neg
Share
Email

Avon Taps Johnson & Johnson's Sherilyn McCoy As CEO - Update

Cosmetics maker Avon Products, Inc. (AVP), which last week rejected a cash bid worth about $10 billion from fragrance maker Coty, Inc., on Monday appointed Sherilyn McCoy as Chief Executive Officer as it aims to execute strong long-term prospects.

McCoy, a 30-year veteran at drug and healthcare major Johnson & Johnson (JNJ), will join Avon on April 23 to succeed Andrea Jung. McCoy, who holds four U.S. patents, will also serve as a director on Avon's Board. Jung, who has been Avon's CEO since 1999, will continue to serve the company as Executive Chairman.

While rejecting Coty's unsolicited bid on March 2 deeming it as "opportunistic and not in the best interest of Avon's shareholders" Avon had said that it remains confident in its prospects as a stand-alone company and remains committed to executing against what it believes are its strong long-term prospects. Avon has been searching for a new CEO after it separated the roles of Chairman and CEO in 2012.

Commenting on the appointment, Avon's lead director Fred Hassan said, "Given her consistent record of outperforming against new challenges, we have great confidence that under Sheri's leadership Avon can successfully execute against our strong long-term prospects."

At Johnson & Johnson, McCoy is currently Vice Chairman of the Executive Committee with responsibility over Pharmaceutical, Consumer, Corporate Office of Science & Technology, and Information Technology divisions. She joined the company in 1982 as a scientist and was appointed to her current responsibilities in January, 2011.

While noting that McCoy would resign from the firm effective April 18, JNJ Chairman and CEO William Weldon said, "During these last several years, she was instrumental in helping to bring stronger strategic focus to our Pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges."

In pre-market activity, Avon shares lost $0.62 or 2.65 percent and are currently trading at $22.80, while JNJ shares lost $0.43 or 0.66 percent and currently at $64.91.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT